NVCT vs. NVO
NVCT (Nuvectis Pharma Inc) and NVO (Novo Nordisk A/S) are both stocks. Both are in the Healthcare sector — NVCT in Biotechnology, NVO in Drug Manufacturers - General. Over the past 3 years, NVCT returned 6.13%/yr vs -11.12%/yr for NVO. At a 0.08 correlation, their price movements are largely independent.
Performance
NVCT vs. NVO - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, NVCT achieves a 143.05% return, which is significantly higher than NVO's 0.65% return.
NVCT
- 1D
- -3.37%
- 1M
- 71.34%
- 6M
- 116.90%
- YTD
- 143.05%
- 1Y
- 132.87%
- 3Y*
- 6.13%
- 5Y*
- —
- 10Y*
- —
NVO
- 1D
- 1.23%
- 1M
- 12.76%
- 6M
- -12.92%
- YTD
- 0.65%
- 1Y
- -24.87%
- 3Y*
- -11.12%
- 5Y*
- 4.91%
- 10Y*
- 8.17%
NVCT vs. NVO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
NVCT Nuvectis Pharma Inc | 143.05% | 39.56% | -35.13% | 11.20% | 89.87% |
NVO Novo Nordisk A/S | 0.65% | -39.22% | -15.93% | 54.84% | 31.30% |
Correlation
The correlation between NVCT and NVO is 0.19, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.19 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.10 |
Correlation (All Time) Calculated using the full available price history since Feb 4, 2022 | 0.08 |
The correlation between NVCT and NVO shifts across timeframes, from 0.08 (all time) to 0.19 (1 year), reflecting how their relationship changes across market environments.
Fundamentals
NVCT:
$486.94M
NVO:
$219.88B
NVCT:
-$1.20
NVO:
DKK 27.42
NVCT:
30.21
NVO:
7.08
NVCT:
$0.00
NVO:
DKK 327.80B
NVCT:
$0.00
NVO:
DKK 268.30B
NVCT:
-$22.01M
NVO:
DKK 181.54B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NVCT vs. NVO — Risk / Return Rank
NVCT
NVO
NVCT vs. NVO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Nuvectis Pharma Inc (NVCT) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NVCT | NVO | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +2.04 | ||
| Sortino ratioReturn per unit of downside risk | +2.72 | ||
| Omega ratioGain probability vs. loss probability | 1.33 | 0.94 | +0.40 |
| Calmar ratioReturn relative to maximum drawdown | 3.50 | -0.55 | +4.05 |
| Martin ratioReturn relative to average drawdown | 6.93 | -0.86 | +7.79 |
Loading charts...
Drawdowns
NVCT vs. NVO - Drawdown Comparison
The maximum NVCT drawdown since its inception was -77.89%, roughly equal to the maximum NVO drawdown of -74.70%. Use the drawdown chart below to compare losses from any high point for NVCT and NVO.
Loading charts...
Drawdown Indicators
| NVCT | NVO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -77.89% | -74.70% | -3.19% |
Max Drawdown (1Y)Largest decline over 1 year | -35.68% | -49.17% | +13.49% |
Max Drawdown (3Y)Largest decline over 3 years | -70.48% | -74.70% | +4.22% |
Max Drawdown (5Y)Largest decline over 5 years | — | -74.70% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -74.70% | — |
Current DrawdownCurrent decline from peak | -35.68% | -64.05% | +28.37% |
Average DrawdownAverage peak-to-trough decline | -52.77% | -17.86% | -34.91% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 17.97% | 31.50% | -13.53% |
Volatility
NVCT vs. NVO - Volatility Comparison
Nuvectis Pharma Inc (NVCT) has a higher volatility of 62.10% compared to Novo Nordisk A/S (NVO) at 8.69%. This indicates that NVCT's price experiences larger fluctuations and is considered to be riskier than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| NVCT | NVO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 62.10% | 8.69% | +53.41% |
Volatility (6M)Calculated over the trailing 6-month period | 71.77% | 37.47% | +34.30% |
Volatility (1Y)Calculated over the trailing 1-year period | 82.61% | 51.76% | +30.85% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 112.50% | 38.52% | +73.98% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 112.50% | 32.59% | +79.91% |
Dividends
NVCT vs. NVO - Dividend Comparison
NVCT has not paid dividends to shareholders, while NVO's dividend yield for the trailing twelve months is around 3.64%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NVCT Nuvectis Pharma Inc | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
NVO Novo Nordisk A/S | 3.64% | 3.31% | 1.68% | 1.00% | 1.20% | 1.35% | 1.87% | 2.14% | 1.45% | 1.52% | 2.87% | 0.92% |
Financials
NVCT vs. NVO - Financials Comparison
This section allows you to compare key financial metrics between Nuvectis Pharma Inc and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
NVCT and NVO have a correlation of 0.19, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
NVCT has higher volatility (62.10%) compared to NVO (8.69%). In terms of maximum drawdown, NVCT dropped -77.89% vs NVO's -74.70%.
NVCT currently has the higher Sharpe Ratio (1.51 vs -0.53), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for NVCT and NVO
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer